Ezogabine

Deutsche Bank is out with an update on Valeant Pharmaceuticals (NYSE: VRX) following the FDA's decision to delay VRX's Ezogabine. The FDA cited non-clinical reasons for the delay. In a note to clients, DB writes, "We maintain our 12 month price target of $30, based on 12x our 2012 cash EPS estimate...